

# Circulating tumour cells in non-metastatic breast cancer

Lancet Oncology, The

13, 688-695

DOI: [10.1016/S1470-2045\(12\)70209-7](https://doi.org/10.1016/S1470-2045(12)70209-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 343.	0.6	22
2	Aromatase inhibitors-induced bone loss in early breast cancer. BoneKEy Reports, 2012, 1, 201.	2.7	10
4	Circulating tumour cells as biomarkers in early breast cancer. Lancet Oncology, The, 2012, 13, 653-654.	5.1	8
5	Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Research, 2012, 14, R133.	2.2	159
6	Circulating and Disseminated Tumor Cells in Breast Cancer. Breast Diseases, 2012, 23, 314-317.	0.0	0
7	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 2012, 10, 192.	1.8	52
8	Circulating tumour cells in early breast cancer. Lancet Oncology, The, 2012, 13, e370.	5.1	2
9	Circulating tumour cells in early breast cancer. Lancet Oncology, The, 2012, 13, e370-e371.	5.1	1
10	Circulating tumour cells in early breast cancer – Authors' reply. Lancet Oncology, The, 2012, 13, e371.	5.1	0
11	Single circulating tumor cell profiling: a new perspective for targeted therapy?. Future Oncology, 2012, 8, 1253-1256.	1.1	4
12	Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumor Biology, 2013, 34, 2507-2509.	0.8	40
13	Essentials of circulating tumor cells for clinical research and practice. Critical Reviews in Oncology/Hematology, 2013, 88, 338-356.	2.0	67
14	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2013, 17, 1809-1818.	0.9	45
15	Detection of cancer before distant metastasis. BMC Cancer, 2013, 13, 283.	1.1	64
18	Luminal breast cancer: from biology to treatment. Nature Reviews Clinical Oncology, 2013, 10, 494-506.	12.5	183
19	Circulating tumor cells: utopia or reality?. Future Oncology, 2013, 9, 1337-1352.	1.1	20
20	Imaging multiple biomarkers in captured rare cells by sequential immunostaining and photobleaching. Methods, 2013, 64, 108-113.	1.9	10
21	Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of Oncology, 2013, 24, 2515-2521.	0.6	36

#	ARTICLE	IF	CITATIONS
22	Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?. <i>Cancer Research</i> , 2013, 73, 6384-6388.	0.4	376
23	Microenvironmental regulation of tumor progression and metastasis. <i>Nature Medicine</i> , 2013, 19, 1423-1437.	15.2	5,730
24	Cell and Molecular Biology of Breast Cancer. , 2013, , .		10
25	A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 409-415.	1.1	29
26	Separation of tumor cells with dielectrophoresis-based microfluidic chip. <i>Biomicrofluidics</i> , 2013, 7, 11803.	1.2	154
27	No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 187-195.	1.1	22
28	Detection and prognostic significance of circulating tumor cells in nonmetastatic breast cancer patients. <i>Breast Cancer Management</i> , 2013, 2, 295-309.	0.2	0
29	Molecular Markers to Predict Response to Therapy. <i>Seminars in Oncology</i> , 2013, 40, 444-458.	0.8	18
30	Skeletal Manifestations of Treatment of Breast Cancer. <i>Current Osteoporosis Reports</i> , 2013, 11, 319-328.	1.5	13
31	Detection and isolation of circulating tumor cells: Principles and methods. <i>Biotechnology Advances</i> , 2013, 31, 1063-1084.	6.0	157
32	The continued evidence from overviews: What is the clinical utility?. <i>Breast</i> , 2013, 22, S8-S11.	0.9	1
33	Follow-up tests to detect recurrent disease: Patient's reassurance or medical need?. <i>Breast</i> , 2013, 22, S156-S160.	0.9	6
34	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
35	Quantification of residual risk of relapse in breast cancer patients optimally treated. <i>Breast</i> , 2013, 22, S92-S95.	0.9	16
36	Translating metastasis-related biomarkers to the clinic—progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 169-179.	12.5	40
37	Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1055-1062.	1.2	45
38	Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 295-307.	1.5	30
39	Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. <i>Cancer Treatment Reviews</i> , 2013, 39, 691-700.	3.4	60

#	ARTICLE	IF	CITATIONS
40	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	12.5	164
41	A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. <i>Clinica Chimica Acta</i> , 2013, 419, 77-84.	0.5	43
42	CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. <i>International Journal of Cancer</i> , 2013, 133, 2398-2407.	2.3	92
43	Circulating Tumor Cells: Personalized Medicine in Interventional Oncology?. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 221-228.	0.2	8
44	Personalizing health care: feasibility and future implications. <i>BMC Medicine</i> , 2013, 11, 179.	2.3	81
45	Folate Receptor-Positive Circulating Tumor Cells as a Novel Diagnostic Biomarker in Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2013, 6, 697-702.	1.7	93
46	Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. <i>Cancers</i> , 2013, 5, 1485-1503.	1.7	8
47	Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. <i>Cancers</i> , 2013, 5, 1619-1642.	1.7	76
48	Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16580-16585.	3.3	196
49	Circulating tumour cells: insights into tumour heterogeneity. <i>Journal of Internal Medicine</i> , 2013, 274, 137-143.	2.7	42
50	Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. <i>International Journal of Breast Cancer</i> , 2013, 2013, 1-5.	0.6	53
51	Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. <i>British Journal of Anaesthesia</i> , 2013, 110, 690-701.	1.5	454
52	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 2426-2432.	2.9	60
53	Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 365-372.	0.8	148
54	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	2.3	245
56	Analysis of Circulating Tumor Cells in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 977-985.	2.3	25
57	Molecular Detection of Peripheral Blood Breast Cancer mRNA Transcripts as a Surrogate Biomarker for Circulating Tumor Cells. <i>PLoS ONE</i> , 2013, 8, e74079.	1.1	14
58	IFN- $\gamma$ Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse. <i>PLoS ONE</i> , 2013, 8, e82544.	1.1	27

#	ARTICLE	IF	CITATIONS
60	Development of a New Rapid Isolation Device for Circulating Tumor Cells (CTCs) Using 3D Palladium Filter and Its Application for Genetic Analysis. PLoS ONE, 2014, 9, e88821.	1.1	69
61	Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients. PLoS ONE, 2014, 9, e102764.	1.1	10
62	Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in Limbo. OncoTargets and Therapy, 2014, 7, 619.	1.0	37
63	Future Directions for the Early Detection of Recurrent Breast Cancer. Journal of Cancer, 2014, 5, 291-300.	1.2	14
64	The Inherent Premise of Immunotherapy for Cancer Dormancy. Cancer Research, 2014, 74, 6745-6749.	0.4	38
65	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6212-6222.	3.2	1,012
67	Metastatic Breast Cancer: Clinical Considerations. , 2014, , 963-970.		0
68	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Journal of the National Cancer Institute, 2014, 106, .	3.0	493
69	Evaluation of Two Different Analytical Methods for Circulating Tumor Cell Detection in Peripheral Blood of Patients with Primary Breast Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	16
71	Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. International Journal of Cancer, 2014, 135, 1978-1982.	2.3	87
72	Circulating Tumor Cells as Biomarkers in Cancer. , 2014, , 1-17.		0
73	Circulating Tumor Microemboli Diagnostics for Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1111-1119.	0.5	61
74	Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology, 2014, 25, 1506-1516.	0.6	186
75	International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Research, 2014, 16, R43.	2.2	43
76	Circulating tumor cells in breast cancer. Journal of Carcinogenesis, 2014, 13, 8.	2.5	21
77	Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry. Head and Neck, 2014, 36, 1207-1215.	0.9	77
78	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. Molecular Diagnosis and Therapy, 2014, 18, 273-284.	1.6	132
79	Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. Journal of the National Cancer Institute, 2014, 106, dju034-dju034.	3.0	47

#	ARTICLE	IF	CITATIONS
80	Circulating Tumor Cells: What Goes Around, Comes Around. Journal of the National Cancer Institute, 2014, 106, .	3.0	0
81	Circulating tumour cellsâ€”a bona fide cause of metastatic cancer. Cancer and Metastasis Reviews, 2014, 33, 747-756.	2.7	46
82	<i>PIK3CA</i> Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer. Clinical Cancer Research, 2014, 20, 5823-5834.	3.2	54
83	Prognostic and Predictive Role of Circulating Tumor Cells in Breast Cancer. Current Breast Cancer Reports, 2014, 6, 251-259.	0.5	1
84	Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. Annals of Oncology, 2014, 25, 2304-2313.	0.6	138
85	The significance of circulating tumour cells in breast cancer: A review. Breast, 2014, 23, 552-560.	0.9	37
86	Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer, 2014, 14, 472.	1.1	45
87	Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cellular and Molecular Life Sciences, 2014, 71, 4393-4402.	2.4	93
88	Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. International Journal of Colorectal Disease, 2014, 29, 1053-1059.	1.0	35
89	American association for cancer research â€” AACR congress 2014. Oncologie, 2014, 16, 341-366.	0.2	0
90	Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2014, 147, 325-333.	1.1	32
91	Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 147, 345-351.	1.1	16
92	Circulating tumor cells as promising novel biomarkers in solid cancers. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 160-171.	2.7	111
93	The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: From Enumeration to Molecular Characterization. Current Breast Cancer Reports, 2014, 6, 146-153.	0.5	12
94	The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy. Future Oncology, 2014, 10, 2555-2560.	1.1	2
95	A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. Clinical Colorectal Cancer, 2014, 13, 94-99.	1.0	28
96	Circulating tumor cells before and during follow-up after breast cancer surgery. International Journal of Oncology, 2015, 46, 407-413.	1.4	52
97	Detection of circulating melanoma cells in the blood of melanoma patients. Melanoma Research, 2015, 25, 335-341.	0.6	19

#	ARTICLE	IF	CITATIONS
98	Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. <i>Thrombosis and Haemostasis</i> , 2015, 113, 593-598.	1.8	30
99	Detecting circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Genetics and Molecular Research</i> , 2015, 14, 10352-10358.	0.3	18
100	New and emerging factors in tumorigenesis: an overview. <i>Cancer Management and Research</i> , 2015, 7, 225.	0.9	27
101	MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. <i>Oncotarget</i> , 2015, 6, 2277-2289.	0.8	56
102	Current Understanding of Circulating Tumor Cells – Potential Value in Malignancies of the Central Nervous System. <i>Frontiers in Neurology</i> , 2015, 6, 174.	1.1	20
103	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	0.7	26
104	Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. <i>PLoS ONE</i> , 2015, 10, e0138032.	1.1	174
105	EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. <i>Oncotarget</i> , 2015, 6, 44623-44634.	0.8	30
106	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. <i>Oncotarget</i> , 2015, 6, 2549-2561.	0.8	96
107	Serial monitoring of circulating tumor <scp>DNA</scp> in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Molecular Medicine</i> , 2015, 7, 1034-1047.	3.3	380
108	Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. <i>Pharmacogenomics</i> , 2015, 16, 669-672.	0.6	1
109	Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 339-349.	1.1	57
110	Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. <i>Breast Diseases</i> , 2015, 26, 311-314.	0.0	1
111	Sampling circulating tumor cells for clinical benefits: how frequent?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 75.	6.9	19
112	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 325-331.	1.1	18
113	Importance of circulating tumor cells in newly diagnosed colorectal cancer. <i>International Journal of Oncology</i> , 2015, 46, 1361-1368.	1.4	87
114	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	1.9	49
115	Circulating tumor cell enumeration by the CellSearch system: The clinician’s guide to breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 144-150.	3.4	62

#	ARTICLE	IF	CITATIONS
116	Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 155-160.	0.4	40
117	Efficient Capture and Simple Quantification of Circulating Tumor Cells Using Quantum Dots and Magnetic Beads. <i>Small</i> , 2015, 11, 2536-2542.	5.2	57
118	Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 535-541.	0.6	60
119	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 2.	2.2	36
120	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer – Advancing from Prognostic to Predictive Potential. <i>Current Breast Cancer Reports</i> , 2015, 7, 53-58.	0.5	0
121	Features of aggressive breast cancer. <i>Breast</i> , 2015, 24, 594-600.	0.9	52
122	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , 2015, 367, 43-48.	3.2	34
123	Breast Cancer Stem Cell Correlates as Predictive Factors for Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2015, 25, 251-259.	1.0	9
124	Biomarkers in Breast Cancer. <i>Advances in Clinical Chemistry</i> , 2015, 71, 1-23.	1.8	86
125	<sup>99m</sup> Tc-dextran lymphoscintigraphy can detect sentinel lymph node in breast cancer patients. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 112-116.	0.8	8
126	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2040-2048.	0.3	66
127	Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 202.	1.1	102
128	Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage III Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 552-558.	0.7	48
129	Efficient capturing of circulating tumor cells using a magnetic capture column and a size-selective filter. <i>Bioprocess and Biosystems Engineering</i> , 2015, 38, 1693-1704.	1.7	10
130	Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. <i>Annals of Oncology</i> , 2015, 26, 1155-1160.	0.6	33
131	Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. <i>British Journal of Cancer</i> , 2015, 112, 1306-1313.	2.9	145
132	Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 232-237.	0.8	19
133	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv250.	3.0	25



#	ARTICLE	IF	CITATIONS
134	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. <i>Clinical Cancer Research</i> , 2015, 21, 4786-4800.	3.2	310
135	The Role of CTCs as Tumor Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 341-367.	0.8	80
136	Biological markers of invasive breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, hv153.	0.6	23
137	Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. <i>BMC Cancer</i> , 2015, 15, 533.	1.1	27
139	Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 51-55.	1.1	1
140	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. <i>Breast</i> , 2015, 24, S6-S10.	0.9	13
141	Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy?. <i>Current Urology Reports</i> , 2015, 16, 46.	1.0	14
142	Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv281.	3.0	3
143	Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 197-225.	0.8	13
144	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
145	Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. <i>Journal of Surgical Oncology</i> , 2015, 111, 81-90.	0.8	30
146	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 278-289.	1.5	19
147	Biology, detection, and clinical implications of circulating tumor cells. <i>EMBO Molecular Medicine</i> , 2015, 7, 1-11.	3.3	453
148	The role of surgeons in building a personalized medicine program. <i>Journal of Surgical Oncology</i> , 2015, 111, 3-8.	0.8	5
149	Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status. <i>Tumor Biology</i> , 2015, 36, 711-718.	0.8	2
150	Circulating Tumor Cells in Breast Cancer Patients. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 125-139.	0.2	22
151	Sodium phenylbutyrate antagonizes prostate cancer through the induction of apoptosis and attenuation of cell viability and migration. <i>OncoTargets and Therapy</i> , 2016, 9, 2825.	1.0	7
152	Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. <i>Journal of Cancer</i> , 2016, 7, 1095-1104.	1.2	73

#	ARTICLE	IF	CITATIONS
153	Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. <i>Oncotarget</i> , 2016, 7, 26724-26738.	0.8	16
154	Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 115-124.	1.3	20
155	Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. <i>Frontiers in Oncology</i> , 2016, 6, 255.	1.3	32
156	Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1775.	1.8	58
157	Circulating tumor cells in breast cancer patients. <i>Neoplasma</i> , 2016, 63, 18-29.	0.7	10
158	Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis. <i>Australasian Journal of Dermatology</i> , 2016, 57, 145-149.	0.4	14
159	Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A-trial. <i>BMC Cancer</i> , 2016, 16, 401.	1.1	14
160	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. <i>Scientific Reports</i> , 2016, 6, 26355.	1.6	25
161	Circulating Tumor Cells. , 2016, , 219-234.		0
162	Predicting Risk of Disease Recurrence. , 2016, , 15-30.		0
163	Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1037-1042.	1.1	61
164	Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients. <i>Clinical Chemistry</i> , 2016, 62, 1002-1011.	1.5	54
165	Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. <i>Hepatology</i> , 2016, 63, 148-158.	3.6	72
166	CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210.	3.2	28
167	Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 173-182.	2.7	19
168	Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. <i>Breast</i> , 2016, 28, 191-198.	0.9	105
169	Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. <i>Science Translational Medicine</i> , 2016, 8, 340ra73.	5.8	178
170	Detection of circulating tumour cells may add value in endometrial cancer management. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 207, 1-4.	0.5	16

#	ARTICLE	IF	CITATIONS
171	Ex vivo culture of circulating tumor cells using magnetic forceâ€based coculture on a fibroblast feeder layer. <i>Biotechnology Journal</i> , 2016, 11, 1433-1442.	1.8	8
172	Circulating tumor cells in breast cancer: applications in personalized medicine. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 411-424.	1.1	44
173	CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. <i>BMC Cancer</i> , 2016, 16, 127.	1.1	56
174	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. <i>European Journal of Cancer</i> , 2016, 63, 97-104.	1.3	44
175	Follow-up strategies for women treated for early breast cancer. <i>The Cochrane Library</i> , 2016, 2016, CD001768.	1.5	138
176	A case report of three patients with metastatic gastric cancer on hemodialysis who were treated with cisplatinâ€fluorouracil regimen. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 345-349.	0.5	3
177	Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. <i>Cell Reports</i> , 2016, 14, 82-92.	2.9	103
178	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 418-430.	2.1	150
179	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
180	Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 211-228.	2.1	7
181	Bone marrow micrometastases in early breast cancerâ€30-year outcome. <i>British Journal of Cancer</i> , 2016, 114, 243-247.	2.9	14
182	Review: circulating tumor cells in the practice of breast cancer oncology. <i>Clinical and Translational Oncology</i> , 2016, 18, 749-759.	1.2	7
183	Metabolomics in Breast Cancer: Current Status and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 217-234.	0.8	28
184	Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 235-258.	0.8	69
186	Genome-Wide Gene Copy Number Analysis of Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , 201-213.	0.2	0
187	Prognostic Implications of CTC in Breast Cancer. <i>Current Cancer Research</i> , 2016, , 233-254.	0.2	0
188	Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. <i>Breast Cancer Research</i> , 2016, 18, 20.	2.2	72
189	Fibroblasts induced epithelial to mesenchymal transition of tumor cells and their extra circulation traveling behavior. <i>Medical Hypotheses</i> , 2016, 89, 24-27.	0.8	1

#	ARTICLE	IF	CITATIONS
190	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
191	Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , .	0.2	6
192	Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1883-1895.	1.2	23
193	Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells. <i>European Spine Journal</i> , 2016, 25, 4008-4015.	1.0	28
194	Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2016, 223, 20-29.	0.2	35
195	Challenges in circulating tumor cell detection by the CellSearch system. <i>Molecular Oncology</i> , 2016, 10, 395-407.	2.1	231
196	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2583-2593.	3.2	289
197	Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 147-164.	1.5	89
198	Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis. <i>Tumor Biology</i> , 2016, 37, 723-727.	0.8	6
200	Circulating tumor cells in breast cancer—current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 22-29.	2.0	36
201	Progress of Circulating Tumor Cells in Cancer Management. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 509-516.	0.8	3
202	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 279-285.	1.1	10
203	Point of care assessment of melanoma tumor signaling and metastatic burden from <sup>1</sup> / <sub>4</sub> NMR analysis of tumor fine needle aspirates and peripheral blood. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 821-828.	1.7	9
204	Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 455-462.	0.9	5
205	Epithelial—mesenchymal transition in tumor metastasis. <i>Molecular Oncology</i> , 2017, 11, 28-39.	2.1	511
206	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 949-962.	0.5	38
207	Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 755-768.	1.1	198
208	Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. <i>Growth Hormone and IGF Research</i> , 2017, 33, 28-34.	0.5	10

#	ARTICLE	IF	CITATIONS
209	Cytologic characteristics of circulating epithelioid cells in pancreatic disease. <i>Cancer Cytopathology</i> , 2017, 125, 332-340.	1.4	30
210	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 501-510.	1.1	13
211	Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis. <i>Oncology Reports</i> , 2017, 37, 3219-3226.	1.2	11
212	Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. <i>Translational Research</i> , 2017, 185, 58-84.e15.	2.2	124
213	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. <i>Seminars in Cancer Biology</i> , 2017, 44, 106-116.	4.3	47
214	The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis. <i>Clinical Cancer Research</i> , 2017, 23, 5112-5122.	3.2	50
216	Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 143-167.	0.8	3
217	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 1-41.	0.8	20
218	Taming the immune system through transfusion in oncology patients. <i>Transfusion and Apheresis Science</i> , 2017, 56, 310-316.	0.5	5
220	Epithelial-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs): The Traveling Metastasis. <i>Cancer Drug Discovery and Development</i> , 2017, , 67-80.	0.2	2
221	Circulating Tumour Cells in Primary Disease: The Seed for Metastasis. <i>Cancer Drug Discovery and Development</i> , 2017, , 15-40.	0.2	0
222	CTCs and ctDNA: Two Tales of a Complex Biology. <i>Cancer Drug Discovery and Development</i> , 2017, , 119-137.	0.2	1
223	Classifying circulating tumor cells to monitor cancer progression. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 153-165.	1.5	9
224	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. <i>Annals of Oncology</i> , 2017, 28, 468-477.	0.6	62
225	Exploratory analysis of local gene groups in breast cancer guided by biological networks. <i>Health and Technology</i> , 2017, 7, 119-132.	2.1	0
226	The role of the XRCC1, XRCC3, and PALB2 genes in the genesis of sporadic breast cancer. <i>Russian Journal of Genetics: Applied Research</i> , 2017, 7, 705-711.	0.4	3
227	The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. <i>Pathobiology</i> , 2017, 84, 264-283.	1.9	16
228	Thrombocytosis as a prognostic factor in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 819-832.	1.1	16

#	ARTICLE	IF	CITATIONS
229	Metastatic efficiency of tumour cells can be impaired by intraoperative cell salvage process: truth or conjecture?. <i>Transfusion Medicine</i> , 2017, 27, 327-334.	0.5	24
230	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. <i>Annals of Surgical Oncology</i> , 2017, 24, 2981-2988.	0.7	30
231	Biological and Molecular Characterization of Circulating Tumor Cells: A Creative Strategy for Precision Medicine?. <i>Advances in Clinical Chemistry</i> , 2017, 82, 71-103.	1.8	3
232	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. <i>Breast</i> , 2017, 34, S13-S18.	0.9	6
234	Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 32-44.	12.5	143
235	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
236	Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 331-370.	0.8	16
237	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	3.6	49
238	Are Liquid Biopsies Applied Across Every Type of Solid Tumours?. <i>Journal of Neoplasm</i> , 2017, 02, .	0.1	0
239	Circulating Tumor Cells in Breast Cancer: A Potential Liquid Biopsy. , 2017, , .		3
240	Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis. <i>Journal of Breast Cancer</i> , 2017, 20, 12.	0.8	40
241	Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1363-1373.	1.0	33
242	Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 34884-34895.	0.8	37
243	Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. <i>Oncology Research and Treatment</i> , 2018, 41, 93-98.	0.8	8
244	Clinical indications for, and the future of, circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 143-150.	6.6	57
245	Circulatory Tumor Cells in Esophageal Adenocarcinoma. <i>Methods in Molecular Biology</i> , 2018, 1756, 177-186.	0.4	3
246	EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas. <i>Cancer Biology and Therapy</i> , 2018, 19, 454-460.	1.5	19
247	Clinical applications of the CellSearch platform in cancer patients. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 102-121.	6.6	185

#	ARTICLE	IF	CITATIONS
248	A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 305-309.	1.1	2
249	Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 785-790.	0.8	6
250	Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer. , 2018, , 858-866.e3.		2
251	<i>ESR1</i> Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 1500-1510.	3.2	125
252	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e180163.	3.4	105
254	Prognostic and predictive biomarkers in breast cancer: Past, present and future. <i>Seminars in Cancer Biology</i> , 2018, 52, 56-73.	4.3	284
255	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
256	Prognostic impact of circulating tumor cells in patients with ampullary cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 5014-5022.	2.0	9
257	Prognostic value of systemic immune-inflammation index (SII) in cancers: a systematic review and meta-analysis. <i>Journal of Laboratory and Precision Medicine</i> , 0, 3, 29-29.	1.1	11
258	Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis. <i>Oncomedicine</i> , 2018, 3, 15-27.	1.1	6
259	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
260	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 83-95.	0.8	10
261	Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. <i>Gastroenterology</i> , 2018, 155, 2016-2018.e11.	0.6	29
262	Hyaluronan arrests human breast cancer cell growth by prolonging the G0/G1 phase of the cell cycle. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 1181-1189.	0.9	8
263	Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. <i>PLoS ONE</i> , 2018, 13, e0204334.	1.1	29
264	ASO Author Reflections: The Whole Transcriptome Landscape of Circulating Tumor Cells in Nonmetastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 646-647.	0.7	0
265	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8
266	Circulating Tumor Cells. <i>Surgical Pathology Clinics</i> , 2018, 11, 679-686.	0.7	11



#	ARTICLE	IF	CITATIONS
267	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 208-212.	0.3	5
268	The Clinical Relevance of Circulating Tumor Cells in Early Breast Cancer. , 0, , .		0
269	Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. <i>Advances in Clinical Chemistry</i> , 2018, 83, 121-181.	1.8	35
270	Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. <i>Tumor Biology</i> , 2018, 40, 101042831877616.	0.8	50
271	A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 171.	1.8	25
272	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	3.4	151
273	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial. <i>Clinical Breast Cancer</i> , 2018, 18, e1103-e1110.	1.1	0
274	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018, 24, 5635-5644.	3.2	88
275	Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1983-1994.	1.1	63
276	RNA-Seq of Circulating Tumor Cells in Stage III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2261-2270.	0.7	45
277	Circulating Hybrid Cells Join the Fray of Circulating Cellular Biomarkers. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 595-607.	2.3	24
278	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. <i>Cells</i> , 2019, 8, 683.	1.8	21
279	PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. <i>Molecular Oncology</i> , 2019, 13, 2515-2530.	2.1	55
280	Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. <i>Cells</i> , 2019, 8, 652.	1.8	44
281	Isolation and characterization of spontaneously immortalized lymphocyte lines from HIV-infected patients with and without non-Hodgkin's Lymphoma. <i>Cancer Medicine</i> , 2019, 8, 6741-6755.	1.3	3
282	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	12.8	393
283	The current status of the clinical utility of liquid biopsies in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1031-1041.	1.5	27
284	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019, 11, 1325.	1.7	7



#	ARTICLE	IF	CITATIONS
285	The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. <i>Journal of Translational Medicine</i> , 2019, 17, 318.	1.8	19
286	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019, 14, e0221305.	1.1	14
287	Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells. <i>Analytical Chemistry</i> , 2019, 91, 3443-3451.	3.2	5
288	Profiling of Invasive Breast Carcinoma Circulating Tumour Cells—Are We Ready for the “Liquid” Revolution?. <i>Cancers</i> , 2019, 11, 143.	1.7	8
289	Application of Circulation Tumor Cells Detection in Diagnosis and Treatment of Breast Tumors. <i>Rejuvenation Research</i> , 2019, 22, 498-502.	0.9	3
290	Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 2805-2811.	0.7	27
291	Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5388-5397.	3.2	27
292	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. <i>Cancers</i> , 2019, 11, 802.	1.7	24
293	Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study. <i>Molecular Oncology</i> , 2019, 13, 1548-1558.	2.1	40
294	The biology and clinical potential of circulating tumor cells. <i>Radiology and Oncology</i> , 2019, 53, 131-147.	0.6	53
295	Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 52-66.	0.5	1
296	EVALUATING MMP-2 AND TGF- $\beta$ -RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2019, 32, e1433.	0.5	9
297	Circulating Tumor Cells in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz026.	1.4	63
298	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019, 25, 4255-4263.	3.2	281
299	Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. <i>Annals of Oncology</i> , 2019, 30, 1114-1120.	0.6	54
301	Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 1829-1837.	0.5	49
302	CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial. <i>BMC Cancer</i> , 2019, 19, 304.	1.1	13
303	Quel avenir pour les biopsies liquides en oncologie thoracique ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 436-443.	0.0	0

#	ARTICLE	IF	CITATIONS
304	Circulating tumor cells detection in tumor draining vein of breast cancer patients. <i>Scientific Reports</i> , 2019, 9, 18195.	1.6	16
306	NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 1961.	1.7	18
307	&lt;p&gt;Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 10791-10800.	0.9	8
308	Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. <i>Methods in Molecular Biology</i> , 2019, 1909, 47-73.	0.4	19
309	Role of Circulating Tumor Cells in Breast Cancer Patients. , 2019, , 383-392.		0
310	Current Progresses of Exosomes as Cancer Diagnostic and Prognostic Biomarkers. <i>International Journal of Biological Sciences</i> , 2019, 15, 1-11.	2.6	188
311	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	3.4	88
312	Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. <i>Cancers</i> , 2019, 11, 59.	1.7	47
313	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. <i>Journal of the National Cancer Institute</i> , 2019, 111, 339-341.	3.0	11
314	Molecular Diagnostics in Breast Cytology. , 2019, , 301-336.		0
315	Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 45-54.	0.2	12
316	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
317	Evaluation of the diagnostic value of circulating tumor cells with CytoSorter <sup>Â</sup> CTC capture system in patients with breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1638-1647.	1.3	40
318	Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032.	1.3	19
319	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	1.6	11
320	Preclinical and Clinical Evaluation of Magnetic-Activated Cell Separation Technology for CTC Isolation in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554554.	1.3	12
321	Quel avenir pour les biopsies liquides en oncologie thoracique ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 25299-25306.	0.0	0
322	Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2621-2630.	1.2	7

#	ARTICLE	IF	CITATIONS
323	Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy. <i>Cancers</i> , 2020, 12, 3588.	1.7	9
324	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. <i>EBioMedicine</i> , 2020, 62, 103100.	2.7	44
325	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 441-452.	1.0	78
326	Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 683-687.	1.1	2
327	Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098010.	0.8	3
328	Detection of Circulating Tumor Cells in Breast Cancer Patients by Nanopore Sensing with Aptamer-Mediated Amplification. <i>ACS Sensors</i> , 2020, 5, 2359-2366.	4.0	43
329	Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 628.	1.3	34
330	Cell free DNA biology and its involvement in breast carcinogenesis. <i>Advances in Clinical Chemistry</i> , 2020, 97, 171-223.	1.8	6
331	Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 815-828.	1.5	4
332	Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer. <i>Scientific Reports</i> , 2020, 10, 10010.	1.6	18
333	Cell surface vimentin $\alpha$ -positive circulating tumor cell $\beta$ -based relapse prediction in a long $\alpha$ -term longitudinal study of postremission neuroblastoma patients. <i>International Journal of Cancer</i> , 2020, 147, 3550-3559.	2.3	19
334	Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1671.	1.8	34
335	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66
336	TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 22.	2.2	10
337	Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer. <i>Oncogene</i> , 2020, 39, 2568-2582.	2.6	34
338	Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer. <i>Cancer Medicine</i> , 2020, 9, 2290-2298.	1.3	8
339	Circulating Tumor Cells in Breast Cancer Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	2
340	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non $\alpha$ -Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. <i>Clinical Lung Cancer</i> , 2021, 22, e451-e465.	1.1	26

#	ARTICLE	IF	CITATIONS
341	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
342	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	1.7	4
343	Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 337-361.	0.8	6
344	Liquid biopsy in chronic liver disease. <i>Annals of Hepatology</i> , 2021, 20, 100197.	0.6	14
345	Circulating Tumor Cells: Brief Overview of Methods for Detection. , 2021, , 1-8.		0
346	Clinical management and biology of tumor dormancy in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 78, 49-62.	4.3	24
347	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
348	Heterogeneous Manifestations of Epithelialâ€“Mesenchymal Plasticity of Circulating Tumor Cells in Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2504.	1.8	15
349	Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma. <i>Cancers</i> , 2021, 13, 1823.	1.7	6
350	New Treatment Strategies for the Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 50.	1.3	10
351	Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 332-350.	0.8	29
352	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. <i>Cancers</i> , 2021, 13, 2189.	1.7	8
353	Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights. <i>Frontiers in Oncology</i> , 2021, 11, 672195.	1.3	34
354	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	1.7	26
355	Early Detection and Dynamic Changes of Circulating Tumor Cells in Transgenic NeuN Transgenic (NTTg) Mice with Spontaneous Breast Tumor Development. <i>Cancers</i> , 2021, 13, 3294.	1.7	2
356	Clusters, Assemblies and Aggregates of Tumor Cells in the Blood of Breast Cancer Patients; Composition, Mode of Action, Detection and Impact on Metastasis and Survival. <i>International Journal of Translational Medicine</i> , 2021, 1, 55-68.	0.1	3
357	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666156.	1.8	12
358	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1037-1048.	1.5	7

#	ARTICLE	IF	CITATIONS
359	Multi-Marker Immunomagnetic Enrichment of Circulating Melanoma Cells. <i>Methods in Molecular Biology</i> , 2021, 2265, 213-222.	0.4	3
360	Liquid Biopsy: Translating Minimally Invasive Disease Profiling from the Lab to the Clinic. , 2019, , 145-167.		1
361	Circulating Tumor Cell Enrichment Technologies. <i>Recent Results in Cancer Research</i> , 2020, 215, 25-55.	1.8	15
362	Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 127-145.	1.8	18
363	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 147-160.	1.8	8
364	Introduction to Biology of Breast Cancer Metastasis and Importance of the Analysis of CTCs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 1-10.	0.8	10
365	Circulating Tumor Cells: Applications for Early Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 135-146.	0.8	5
366	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 571-580.	1.1	12
367	Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model. <i>PLoS ONE</i> , 2013, 8, e58183.	1.1	35
368	Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e62153.	1.1	12
369	Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e75038.	1.1	114
370	Mesenchymal Phenotype of CTC-Enriched Blood Fraction and Lymph Node Metastasis Formation Potential. <i>PLoS ONE</i> , 2014, 9, e93901.	1.1	43
371	Detection and Quantitation of Circulating Tumor Cell Dynamics by Bioluminescence Imaging in an Orthotopic Mammary Carcinoma Model. <i>PLoS ONE</i> , 2014, 9, e105079.	1.1	13
372	The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. <i>PLoS ONE</i> , 2017, 12, e0173593.	1.1	43
373	Surveillance and Monitoring in Breast Cancer Survivors: Maximizing Benefit and Minimizing Harm. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e13-e18.	1.8	6
374	CIRCULATING TUMOR CELLS: CLINICAL SIGNIFICANCE IN BREAST CANCER (REVIEW). <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2017, 72, 450-457.	0.2	8
375	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	0.8	44
376	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93

#	ARTICLE	IF	CITATIONS
377	Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells. <i>Oncotarget</i> , 2017, 8, 8801-8806.	0.8	28
378	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	0.8	36
379	Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer. , 2019, 2, 1215-1223.		2
380	The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 519-529.	0.6	7
381	Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer – The SUCCESS Trial. <i>Anticancer Research</i> , 2016, 36, 4771-4776.	0.5	11
382	Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 1787-1791.	0.5	6
383	Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 2727-2734.	0.5	11
384	Prognostic relevance of minimal residual disease in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 10296.	1.4	47
385	Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma: A case report. <i>World Journal of Gastroenterology</i> , 2015, 21, 7921.	1.4	19
386	Circulating tumor cells and breast cancer-specific mutations in primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 565-573.	0.4	4
387	Epithelial-mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC. <i>Molecular Medicine Reports</i> , 2019, 19, 601-608.	1.1	19
388	CTC enumeration and characterization: moving toward personalized medicine. <i>Annals of Translational Medicine</i> , 2014, 2, 108.	0.7	83
389	Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series. <i>The Journal of Breast Health</i> , 2020, 16, 129-136.	0.4	8
390	Liquid Biopsy in Breast Cancer: A Focused Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 678-686.	1.2	64
391	Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers. <i>Journal of Cancer Research Updates</i> , 2015, 4, .	0.3	9
392	Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases. <i>Clinics</i> , 2021, 76, e2971.	0.6	2
394	Metastatic Determinants: Breast Tumour Cells in Circulation. , 2013, , 191-209.		0
395	Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC). , 2013, , .		0

#	ARTICLE	IF	CITATIONS
396	Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer. , 2014, , 119-132.		0
398	Circulating Tumor Cells as Biomarkers in Cancer. Biomarkers in Disease, 2015, , 31-51.	0.0	3
399	The role of XRCC1, XRCC3 and PALB2 genes in the genesis of breast cancer. Ecological Genetics, 2015, 13, 91.	0.1	1
400	Bone Marrow Micrometastases and Circulating Tumor Cells. , 2016, , 229-239.		0
401	Detection of Recurrence: Clinical Follow-Up. , 2016, , 31-40.		0
402	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa). , 2017, , 47-59.		0
403	CXCR4 EXPRESSION IN DIFFERENT SUBSETS OF CTCs AND SINGLE (DETACHED) BREAST CANCER CELLS. Siberian Journal of Oncology, 2018, 17, 75-80.	0.1	2
404	Wytwarzanie separatorów krwotocznych komórek nowotworowych metodami ablacji laserowej. Inżynieria Powierzchni, 2018, 24, 37-43.	0.1	0
406	Bone Marrow Micrometastases and Circulating Tumor Cells. , 2019, , 191-199.		1
408	Circulating tumor cells and drug history in primary breast cancer patients. , 2020, 3, 98-109.		0
409	Circulating Tumor Cells as Biomarkers in Pancreatic Cancer. Molecular and Translational Medicine, 2020, , 129-143.	0.4	0
410	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Frontiers in Pharmacology, 2021, 12, 747194.	1.6	14
411	Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma – Mini Review. Cancer Management and Research, 2021, Volume 13, 8355-8365.	0.9	8
413	Notes for developing a molecular test for the full characterization of circulating tumor cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 471-8.	0.7	1
414	The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biology and Medicine, 2016, 13, 19-40.	1.4	12
415	Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. American Journal of Translational Research (discontinued), 2017, 9, 2807-2823.	0.0	10
416	Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. Indian Journal of Medical Research, 2017, 146, 563-571.	0.4	3
418	Tumour Markers, Prognostic and Predictive Factors in Breast Cancer. , 2022, , 221-241.		3



#	ARTICLE	IF	CITATIONS
419	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	1.7	7
420	The potential of liquid biopsy in the management of cancer patients. <i>Seminars in Cancer Biology</i> , 2022, 84, 69-79.	4.3	55
421	Coagulation and inflammation in cancer: Limitations and prospects for treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188727.	3.3	9
422	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	0.8	139
428	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	1.8	4
429	Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6271.	1.8	9
430	Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 1057-1067.	1.1	1
431	Tumor regionalization after surgery: Roles of the tumor microenvironment and neutrophil extracellular traps. <i>Experimental and Molecular Medicine</i> , 2022, 54, 720-729.	3.2	22
432	Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
433	Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research. <i>Nature Communications</i> , 2022, 13, .	5.8	1
434	Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7843.	1.8	15
435	Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1941-1950.	1.2	1
436	Circulating Cells with Macrophage-like Characteristics in Cancer: The Importance of Circulating Neoplastic-Immune Hybrid Cells in Cancer. <i>Cancers</i> , 2022, 14, 3871.	1.7	19
437	Bioplatfroms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
438	The Novel Association of Early Apoptotic Circulating Tumor Cells with Treatment Outcomes in Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9475.	1.8	5
439	Cancer Biomarkers in the Era of Systems Biology. , 2022, , 51-70.		2
441	Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
442	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2



#	ARTICLE	IF	CITATIONS
443	Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
444	Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12141.	1.8	7
445	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. <i>Cancers</i> , 2022, 14, 5668.	1.7	3
446	Clinical significance of circulating tumor cell (CTC)-specific microRNA (miRNA) in breast cancer. <i>Progress in Biophysics and Molecular Biology</i> , 2022, , .	1.4	4
447	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 161-182.	2.7	10
448	Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. <i>Cancers</i> , 2023, 15, 96.	1.7	2
449	Circulating Tumor Cells in Breast Cancer. , 2023, , .		0
450	Circulating Tumour Cells in Solid Cancer. , 2023, , 115-147.		0
451	Circulating Tumor Cell Detection by Liquid Biopsy during Early-Stage Endometrial Cancer Surgery: A Pilot Study. <i>Biomolecules</i> , 2023, 13, 428.	1.8	1
452	Liquid Biopsies, Novel Approaches and Future Directions. <i>Cancers</i> , 2023, 15, 1579.	1.7	18
453	Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the "NSCLC" of GI Oncology?. <i>Cancers</i> , 2023, 15, 1578.	1.7	8
454	Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. <i>Diagnostics</i> , 2023, 13, 1032.	1.3	0
455	Significance of circulating tumor cells in lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 877-894.	1.3	2
456	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
457	Utilization of Circulating Tumor Cells in the Management of Solid Tumors. <i>Journal of Personalized Medicine</i> , 2023, 13, 694.	1.1	2
462	Zirkulierende Tumorzellen. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0
467	CTCs in Early Breast Cancer. <i>Current Cancer Research</i> , 2023, , 463-490.	0.2	0
470	Liquid biopsy: from concept to clinical application. <i>Scientific Reports</i> , 2023, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------